Drug Trial Radar · NCT06654791
Mass Balance Clinical Trial of SIM0270
Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Oct 17, 2024
Primary completion
Mar 31, 2025
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Nanjing Zaiming Pharmaceutical Co., Ltd.
- First posted
- Oct 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, non-randomized, open-label, single-cohort, single-dose phase I clinical study in healthy Chinese adult male subjects.
Conditions
- Healthy Participants
Interventions
[14C] SIM0270 Oral PreparationDrug
Use according to the prescribed protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]SIM0270 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection PeriodTime frame: From Day 1 to Day 44
- Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) of [14C]SIM0270 Recovered in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection PeriodTime frame: From Day 1 to Day 44
- Maximum 0bserved Concentration (Cmax), Estimated for SIM0270 in Plasma and for Total Radioactivity in PlasmaTime frame: From 0 to 432 hours
- Time to Maximum 0served Concentration (Tmax), Estimated for SIM0270 in Plasma and for Total Radioactivity in PlasmaTime frame: From 0 to 432 hours
- Area Under the Concentration-Time Curve From Time 0 to 432 Hours AUC(0-432), Estimated for SIM0270 in Plasma and for Total Radioactivity in PlasmaTime frame: From 0 to 432 hours
- Terminal Elimination Half-Life (t1/2), Estimated for SIM0270 in Plasma and for Total Radioactivity in PlasmaTime frame: From 0 to 432 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.